Comparing an AI test to a 21-gene assay for premenopausal node-positive HR+/HER2-breast cancer

medRxiv 2026 Preprint Open access

Read full text
Authors: Jailan A. Elayoubi, Cerise Tang, Kathryn J. Ruddy, Khalil Choucair, Kevin M. Kalinsky, Katarzyna Pogoda, Francisco J. Esteva, Jad M. Abdelsattar, Virginia F. Borges, Ken Zeng, Joseph Cappadona, Bartosz Machura
+3 more Dhruva Biswas, Krzysztof J. Geras, Jan Witowski
DOI: 10.64898/2026.02.06.26345771
Cited by: 1
References: 15

Abstract

Abstract Recurrence scores based on a 21-gene assay are clinically useful for predicting prognosis and chemotherapy benefit in postmenopausal node-positive breast cancer patients, but its performance in premenopausal patients is inconsistent. Here, we evaluated Ataraxis Breast RISK (ATX), an AI test that predicts recurrence risk, and compared it with the genomic assay. ATX identified high risk patients misclassified as low risk by the genomic assay and therefore may refine selection of patients for adjuvant chemotherapy.

Fields of Study & Subjects

Breast Cancer Treatment Studies BRCA gene mutations in cancer HER2/EGFR in Cancer Research

Publication details

Journal / source
medRxiv
Publisher
openRxiv
Publication date
9 February 2026
Document type
Preprint